Jyong Biotech (MENS) Competitors $59.08 -2.42 (-3.93%) As of 02:25 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock MENS vs. GMAB, VTRS, ASND, RDY, QGEN, BBIO, MRNA, VRNA, ELAN, and ROIVShould you be buying Jyong Biotech stock or one of its competitors? The main competitors of Jyong Biotech include Genmab A/S (GMAB), Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Jyong Biotech vs. Its Competitors Genmab A/S Viatris Ascendis Pharma A/S Dr. Reddy's Laboratories QIAGEN BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Jyong Biotech (NASDAQ:MENS) and Genmab A/S (NASDAQ:GMAB) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership. Is MENS or GMAB more profitable? Genmab A/S has a net margin of 37.53% compared to Jyong Biotech's net margin of 0.00%. Genmab A/S's return on equity of 21.03% beat Jyong Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Jyong BiotechN/A N/A N/A Genmab A/S 37.53%21.03%16.98% Which has preferable valuation and earnings, MENS or GMAB? Genmab A/S has higher revenue and earnings than Jyong Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJyong BiotechN/AN/AN/AN/AN/AGenmab A/S$3.12B5.75$1.14B$1.9914.07 Does the media refer more to MENS or GMAB? In the previous week, Genmab A/S had 6 more articles in the media than Jyong Biotech. MarketBeat recorded 11 mentions for Genmab A/S and 5 mentions for Jyong Biotech. Genmab A/S's average media sentiment score of 1.27 beat Jyong Biotech's score of 0.59 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jyong Biotech 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of MENS or GMAB? 7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts prefer MENS or GMAB? Genmab A/S has a consensus target price of $39.25, indicating a potential upside of 40.17%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts plainly believe Genmab A/S is more favorable than Jyong Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Genmab A/S 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.70 SummaryGenmab A/S beats Jyong Biotech on 12 of the 12 factors compared between the two stocks. Get Jyong Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MENS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MENS vs. The Competition Export to ExcelMetricJyong BiotechPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$4.49B$860.33M$2.56B$10.27BDividend YieldN/A4.84%2.52%4.60%P/E RatioN/A1.1726.5926.37Price / SalesN/A119.80215.0388.69Price / CashN/A19.5650.2629.91Price / BookN/A6.6633.906.28Net IncomeN/A-$4.13M$15.01M$270.67M7 Day Performance6.11%8.33%1.57%2.79%1 Month Performance32.05%7.85%4.34%6.01%1 Year PerformanceN/A25.87%35.67%26.05% Jyong Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MENSJyong BiotechN/A$59.08-3.9%N/AN/A$4.49BN/A0.0031News CoverageGMABGenmab A/S3.9536 of 5 stars$24.87-1.0%$37.60+51.2%+3.4%$15.96B$3.12B14.542,682Positive NewsVTRSViatris1.4987 of 5 stars$10.55+1.3%$10.40-1.4%-14.6%$12.30B$14.74B4.3832,000ASNDAscendis Pharma A/S3.1839 of 5 stars$194.27+0.2%$243.36+25.3%+64.0%$11.89B$393.54M0.001,017Positive NewsRDYDr. Reddy's Laboratories2.2911 of 5 stars$14.20-0.1%$16.95+19.4%-8.9%$11.86B$3.81B21.5127,811News CoveragePositive NewsQGENQIAGEN4.443 of 5 stars$46.53+0.9%$49.69+6.8%+0.5%$10.34B$1.98B19.825,765BBIOBridgeBio Pharma4.4423 of 5 stars$51.76-1.5%$62.18+20.1%+95.6%$9.89B$221.90M0.00400Analyst ForecastMRNAModerna4.482 of 5 stars$24.09-1.6%$42.88+78.0%-65.6%$9.37B$3.24B0.005,800VRNAVerona Pharma PLC American Depositary Share2.3109 of 5 stars$105.91+0.0%$109.00+2.9%+257.4%$9.16B$42.28M0.0030Positive NewsELANElanco Animal Health2.6297 of 5 stars$18.38-0.4%$17.33-5.7%+28.0%$9.12B$4.44B20.399,000High Trading VolumeROIVRoivant Sciences3.1479 of 5 stars$11.93-0.1%$16.50+38.3%+17.9%$8.15B$29.05M0.00860Positive News Related Companies and Tools Related Companies GMAB Alternatives VTRS Alternatives ASND Alternatives RDY Alternatives QGEN Alternatives BBIO Alternatives MRNA Alternatives VRNA Alternatives ELAN Alternatives ROIV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MENS) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jyong Biotech Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jyong Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
